Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses the need for global value assessments to be adaptable for countries that place emphasis on certain values.
Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses the need for global value assessments to be adaptable for countries that place emphasis on certain values.
Transcript
Is there a need for a global value assessment to be adaptable to different countries who might place emphasis on certain values?
I think that’s going to be very important. So, while we do have conventional cost-effectiveness and it works quite well, it’s also very context specific. So, take one example: people have come up with this concept called the fair innings argument. It basically says that there may be some cases where individuals live a shorter amount of time. So, if you’re a really sick young infant, if you’re a really sick young kid, your life expectancy might be much shorter than someone who lives a full lifespan. And because of that, we might want some concept of equity where we think about, maybe we want to value the treatments that are going to treat patients that are very sick, very young, maybe those with rare diseases more than we value a treatment that affects the entire population. So, these are all equity considerations that are really, they’re not mathematical. They reflect the value of a particular society.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More